Three “P”s Healthcare Marketers Must Chase

Three Ps Healthcare Marketers Must Chase 1 As the healthcare landscape changes, three targets emerge as the groups that will determine the success or failure of pharma, medical device and other life science products. 1. Providers (Not Just Physicians) In the MM&M Healthcare Marketers Trend Report, 64% of director and C-suite level life science execs […]

FacebookTwitter

Purdue, Teva and J&J Sued Over Opioid Overdoses

Purdue, Teva and J&J Sued Over Opioid Overdoses 1   A new government study found that more than one third of U.S. adults were prescribed opioid medications in 2015. Though many chronic pain sufferers legitimately require these meds to manage pain, the increased number of people taking opioids increases risks associated with them. These addictive […]

FacebookTwitter

New FDA Commissioner’s Goals

New FDA Commissioner’s Goals 1 The new FDA commissioner Dr. Scott Gottlieb, who was confirmed in May, has made his main goal clear: streamlining FDA operations to get new generic drugs and medical devices available more quickly. An analysis by the FDA suggests that the introduction of two generic versions of a drug cuts the […]

FacebookTwitter

Three MD to NP Comparisons

A new study shows Nurse Practitioner (NP) visits correlate to a big drop in hospital admissions. Hospitalization rates plummeted 61%, and ER visits fell 64% among a group of patients who received home visits from NPs during a six-month period in 2016, according to a University of Rhode Island College of Nursing study. Previous studies show similar results proving that NPs can reduce hospitalizations and close a problematic gap between the hospital and primary care that MDs cannot address alone. Continue reading…

FacebookTwitter

Future of Off-Label Promotion

Between Dr. Gottlieb being sworn in as the new FDA commissioner and several recent court cases going in favor of the drugmakers, one has to question if we’ll see a loosening of off-label promotion rules. It’s estimated that one in five prescriptions written in the U.S. are for off-label therapies, and studies have shown much higher percentages of off-label use in certain specialties. Continue reading…

FacebookTwitter
1 2 3 4 5 11